title: [Complete response of advanced rectal cancer with combined therapy of S-1 + chemo-radiation plus FOLFIRI--a case report].
abstract: A 64-year-old man was admitted to general practitioner because of dyschezia. He was diagnosed with lower rectal cancer by colonoscopy and referred to our hospital for therapy. At first, in spite of multiple liver metastases, we tried a resection of primary lesion in order to control of breeding, dyschezia and pain. However, we had to give up the resection, so we made sigmoid colostomy only. One month after the operation, a combination chemo-radiotherapy using S-1 was performed for controlling of local symptom. S-1 (120 mg/day) was administered on days 1-14, and 21-35. Radiation (2 Gy) was administered on days 1-5, 7-12, 14-19, 21-26, 28-33, and 35-40, a total of 60 Gy. One month after this therapy, the tumor was remarkably reduced and the reduction was judged as partial response. Moreover after 6 courses of FOLFIRI, the reduction was judged as complete response. Local control therapy (S-1+chemo-radiation) plus systemic therapy (FOLFIRI) is one of the promising effective therapies for advanced rectal cancer.
authors.affiliation: Dept. of Surgery, Toyonaka Municipal Hospital.
authors.forename: Taishi
authors.initials: T
authors.lastname: Hata
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Kagawa
authors.forename: Kimimasa
authors.initials: K
authors.lastname: Ikeda
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kato
authors.forename: Kaori
authors.initials: K
authors.lastname: Takamoto
authors.forename: Noriko
authors.initials: N
authors.lastname: Oshima
authors.forename: Sakae
authors.initials: S
authors.lastname: Maeda
authors.forename: Motonari
authors.initials: M
authors.lastname: Nomura
authors.forename: Shouho
authors.initials: S
authors.lastname: Hayashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Sasaki
authors.forename: Junzo
authors.initials: J
authors.lastname: Shimizu
authors.forename: Kensyu
authors.initials: K
authors.lastname: Kawanishi
authors.forename: Junya
authors.initials: J
authors.lastname: Fujita
authors.forename: Kenzo
authors.initials: K
authors.lastname: Akagi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Tsukahara
authors.forename: Masashi
authors.initials: M
authors.lastname: Kitada
authors.forename: Takashi
authors.initials: T
authors.lastname: Shimano
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004338:Drug Combinations; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D011351:Proctoscopy; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D012074:Remission Induction; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D014408:Biomarkers, Tumor; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin